Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor?

Nicholas A. Keks, Judy Hope, Christine Culhane

Research output: Contribution to journalArticleOtherpeer-review

5 Citations (Scopus)


Objective: The treatment of depressive disorders remains unsatisfactory for many patients with regard to efficacy and tolerability. Vortioxetine has been registered by regulatory authorities for the treatment of major depressive disorder. This paper aims to provide clinicians with a brief overview of vortioxetine and its place in treatment. Conclusions: Vortioxetine is a serotonin reuptake inhibitor with additional serotonergic receptor effects of uncertain significance; hence, its classification as 'multimodal'. The half-life is about 2.75 days and steady state requires about 14 days. Metabolism is hepatic and involves cytochromes 2D6 and 3A4/5. Antidepressant efficacy in major depressive disorder has been established in registration studies, but the effectiveness of vortioxetine in 'real world' patients and in comparison to other antidepressants needs further investigation. The recommended dose range is 5-20 mg. Nausea, constipation and vomiting are the most common side effects. Sexual dysfunction may occur at higher doses but there appears to be low risk of weight gain and sedation. There is still much to learn about this drug, particularly whether it has unique characteristics in comparison to existing antidepressants. At present, vortioxetine can be considered as an antidepressant option in patients with established major depressive disorder who have not responded adequately to other antidepressants.

Original languageEnglish
Pages (from-to)210-213
Number of pages4
JournalAustralasian Psychiatry
Issue number3
Publication statusPublished - 1 Jan 2015


  • Major depressive disorder
  • Pharmacotherapy
  • Vortioxetine

Cite this